Citius Pharmaceuticals, Inc. — Key Metrics
17 years of history · ending 2025-09-30 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
Z-Score (Altman; <1.81 = distress)
Per Share Metrics
Turnover & Efficiency Analysis (days)
Expense Ratios
Working Capital Analysis
Valuation Multiples
Enterprise Value Multiples
52-Week Range
Trailing Returns
ROIC vs WACC
Yields
Capital Deployment Yields
EPS (Diluted)↓-1591.8% -$3
$-4
Book Value Per Share↑+399.3% +$5
$6
Free Cash Flow Per Share↓-974.3% -$2
$-2
Cash Per Share↓-40.4% -$0
$0
Revenue Per Share
$0
OCF Per Share↓-974.6% -$2
$-2
Return on Equity↓-28.4pts
-56.1%
Return on Assets↓-7.3pts
-32.1%
Return on Invested Capital↓-20.6pts
-43.0%
Current Ratio↓-96.6% -$18
0.62
Quick Ratio↓-99.3% -$18
0.13
Asset Turnover↓-74.0% -$0
0.00
Days Payables Outstanding
7657.43
R&D / Revenue↑+10866.6pts
19617.2%
SBC / Revenue↑+3300.3pts
4339.9%
Capex / Revenue↑+3.5pts
7.7%
Working Capital↓-124.7% -$86M
$-17M
Net Current Asset Value↓-140.3% -$89M
$-25M
Invested Capital↓-49.1% -$65M
$68M
OCF / Net Income↓-36.5% -$0
0.67
FCF / Net Income↓-36.5% -$0
0.67
Accruals Ratio (Sloan)↓-10.9pts
-10.1%
Net Debt↑+93.9% +$66M
$-4M
Net Debt / EBITDA↓-96.3% -$3
0.11
Interest Coverage↑+64.3% +$1K
-774.38
Cash Coverage↑+76.1% +$2K
-533.72
Capex Coverage↑+6.8% +$254
-3495.30
Tangible Common Equity↓-52.8% -$65M
$58M
TCE / Total Assets↓-42.2pts
44.5%
Goodwill / Total Assets↑+0.6pts
7.1%
NOPAT↓-63.7% -$12M
$-30M
Cash ROIC↓-8.3pts
-37.5%
WC / Revenue↑+35315.5pts
44482.5%
Capex / D&A↑+475.7% +$4
4.65
Reinvestment Rate↑+0.0pts
0.0%
Asset Growth vs Revenue Growth↑+2.9pts
-20.0%
Revenue 5Y CAGR
12.5%
Book Value 5Y CAGR↓-36.3pts
14.9%
Stock Price (FY-end)↓-97.6% -$50
$1
Market Cap↓-99.8% -$5.50B
$14M
P/S Ratio
49099.92
P/B Ratio↓-99.5% -$41
0.20
P/TB Ratio↓-99.5% -$44
0.24
Enterprise Value↓-99.8% -$5.43B
$9M
EV / Sales
48636.45
FCF Yield↓-193.1pts
-193.5%
Shareholder Yield↓-79.0pts
-79.0%
R&D Yield↑+66.5pts
66.7%
Capex Yield
0.0%
Shares Variation (YoY)↓-438.8pts
64.5%
Beta (5Y)↑+306.3% +$1
0.95
Cost of Equity↑+3.6pts
9.2%
52W High↓-87.7% -$93
$13
52W Low↓-97.0% -$22
$1
Trailing Return 1Y↓-185.6pts
-90.4%
Trailing Return 5Y↓-17.2pts
-95.2%
F-Score (Piotroski)↑+50.0% +$1
3.00
Z-Score (Altman)
248.63
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.